Preeclampsia (PE) remains a major cause of maternal/fetal morbidity–mortality worldwide. The first stage of PE is characterized by placental hypoxia due to a relative reduction in uteroplacental blood flow, resulting from restricted trophoblast invasion. However, hypoxia is also an essential element for the success of invasion. Under hypoxic conditions, 2-methoxyestradiol (2-ME) could induce the differentiation of cytotrophoblast cells into an invasive phenotype in culture. 2-Methoxyestradiol is generated by catechol-O-methyltransferase, an enzyme involved in the metabolic pathway of estrogens. During pregnancy, circulating 2-ME levels increase significantly when compared to the menstrual cycle. Interestingly, plasma levels of 2-ME are lower in women with PE than in controls, and these differences are apparent weeks or even months before the clinical manifestations of the disease. This article reviews the metabolic pathways involved in 2-ME synthesis and discusses the roles of these pathways in normal and abnormal pregnancies, with particular emphasis on PE.
ACOG technical bulletin. Hypertension in pregnancy. Number 219—January 1996 (replaces no. 91, February 1986). Committee on technical bulletins of the American college of obstetricians and gynecologists. Int J Gynaecol Obstet. 1996;53(2):175–183.
2.
BellamyLCasasJPHingoraniADWilliamsDJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
3.
McDonaldSDMalinowskiAZhouQYusufSDevereauxPJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156(5):918–930.
4.
. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–S22.
5.
KnoflerMPollheimerJ. IFPA award in placentology lecture: molecular regulation of human trophoblast invasion. Placenta. 2012;33(suppl):S55–S62.
6.
NessRBRobertsJM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 1996;175(5):1365–1370.
7.
BorzychowskiAMSargentILRedmanCW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11(5):309–316.
8.
RedmanCW. Current topic: pre-eclampsia and the placenta. Placenta. 1991;12(4):301–308.
9.
PijnenborgRVercruysseLBrosensI. Deep placentation. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):273–285.
10.
HunkapillerNMFisherSJ. Chapter 12. Placental remodeling of the uterine vasculature. Methods Enzymol. 2008;445:281–302.
11.
WhitleyGSCartwrightJE. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. J Anat. 2009;215(1):21–26.
12.
LyallF. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol. 2006;46(4):266–273.
13.
BrosensIARobertsonWBDixonHG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1:177–191.
14.
KhongTYDe WolfFRobertsonWBBrosensI. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10):1049–1059.
15.
RodeschFSimonPDonnerCJauniauxE. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992;80(2):283–285.
16.
GenbacevOZhouYLudlowJWFisherSJ. Regulation of human placental development by oxygen tension. Science. 1997;277(5332):1669–1672.
WangGLSemenzaGL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–1237.
19.
MaxwellPHWiesenerMSChangGWThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
20.
CaniggiaIMostachfiHWinterJHypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000;105(5):577–587.
21.
LibrachCLWerbZFitzgeraldML. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol. 1991;113(2):437–449.
22.
LeeSBWongAPKanasakiKPreeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol. 2010;176(2):710–720.
23.
RedmanCWSacksGPSargentIL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 pt 1):499–506.
24.
KanasakiKPalmstenKSugimotoHDeficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453(7198):1117–1121.
25.
LaValleeTMZhanXHHerbstrittCJKoughECGreenSJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002;62(13):3691–3697.
26.
SchumacherGKataokaMRothJAMukhopadhyayT. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res. 1999;5(3):493–499.
ZachariaLCJacksonEKGillespieDGDubeyRK. Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension. 2001;37(2 part 2):658–662.
29.
ShangWKonidariI, Schomberg DW. 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod. 2001;65(2):622–627.
30.
BeckerCMRohwerNFunakoshiT. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol. 2008;172(2):534–544.
31.
LakhaniNJSarkarMAVenitzJ, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 2003;23(2):165–172.
32.
PasquierESinnappanSMunozMAKavallarisM. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010;9(5):1408–1418.
33.
HouYMeyersCYAkomeahM. A short, economical synthesis of 2-methoxyestradiol, an anticancer agent in clinical trials. J Org Chem. 2009;74(16):6362–6364.
34.
BergDSonsallaRKussE. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983;103(2):282–288.
35.
BarnesCMMcElrathTFFolkmanJHansenAR. Correlation of 2-methoxyestradiol levels in cord blood and complications of prematurity. Pediatr Res. 2010;67(5):545–550.
36.
Pérez-SepúlvedaATorresMJValenzuelaFJLow 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. Prenat Diagn. 2012;32(11):1–6.
37.
MannistoPTKaakkolaS. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51(4):593–628.
38.
PalmerKSaglamBWhiteheadCStockOLappasMTongS. Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. Am J Pathol. 2011;178(6):2484–2488.
39.
LachmanHMPapolosDFSaitoTYuYMSzumlanskiCLWeinshilboumRM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–250.
40.
SyvanenACTilgmannCRinneJUlmanenI. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics. 1997;7(1):65–71.
StanleyJLAnderssonIJPoudelRSildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension. 2012;59(5):1021–1028.
43.
BarneaERMacLuskyNJDeCherneyAHNaftolinF. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol. 1988;5(2):121–127.
44.
RotenLTFenstadMHForsmoSA low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2). Mol Hum Reprod. 2011;17(7):439–446.
45.
LimJHKimSYKim doJGenetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17alpha in preeclampsia. Pharmacogenet Genomics. 2010;20(10):605–610.
46.
LiangSLiuXFanPAssociation between Val158Met functional polymorphism in the COMT gene and risk of preeclampsia in a Chinese population. Arch Med Res. 2012;43(2):154–158.
47.
HillLDYorkTPKusanovicJPEpistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One. 2011;6(1):e16681.
48.
AnanthCVElsasserDAKinzlerWLPolymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: risk of placental abruption. Mol Genet Metab. 2007;91(1):104–110.
49.
SharmaPSenthilkumarRDBrahmachariVMining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis. 2006;5:1.
50.
WalkerMCSmithGNPerkinsSLKeelyEJGarnerPR. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol. 1999;180(3 pt 1):660–664.
51.
CikotRJSteegers-TheunissenRPThomasCMde BooTMMerkusHMSteegersEA. Longitudinal vitamin and homocysteine levels in normal pregnancy. Br J Nutr. 2001;85(1):49–58.
52.
MurphyMMScottJMMcPartlinJMFernandez-BallartJD. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr. 2002;76(3):614–619.
53.
Steegers-TheunissenRPWathenNCEskesTKvan Raaij-SeltenBChardT. Maternal and fetal levels of methionine and homocysteine in early human pregnancy. Br J Obstet Gynaecol. 1997;104(1):20–24.
54.
PowersRWEvansRWMajorsAKPlasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol. 1998;179(6 pt 1):1605–1611.
55.
WangJTrudingerBJDuarteNWilckenDEWangXL. Elevated circulating homocyst(e)ine levels in placental vascular disease and associated pre-eclampsia. BJOG. 2000;107(7):935–938.
56.
D'AnnaRBavieraGCorradoFIentileRGraneseDStellaNC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand. 2004;83(2):155–158.
57.
MakedosGPapanicolaouAHitoglouAHomocysteine, folic acid and B12 serum levels in pregnancy complicated with preeclampsia. Arch Gynecol Obstet. 2007;275(2):121–124.
58.
Lopez-QuesadaEVilasecaMALaillaJM. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2003;108(1):45–49.
59.
CotterAMMolloyAMScottJMDalySF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia. Am J Obstet Gynecol. 2003;189(2):391–394.
60.
RobertsonLWuOLanghornePThrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–196.
61.
ValenzuelaFJPerez-SepulvedaATorresMJCorreaPRepettoGMIllanesSE.Pathogenesis of preeclampsia: the genetic component. J Pregnancy. 2012;2012:632732.
TroisiRPotischmanNRobertsJMCorrelation of serum hormone concentrations in maternal and umbilical cord samples. Cancer Epidemiol Biomarkers Prev. 2003;12(5):452–456.
64.
GhorashiVSheikhvatanM. The relationship between serum concentration of free testosterone and pre-eclampsia. Endokrynol Pol. 2008;59(5):390–392.
65.
CarlsenSMRomundstadPJacobsenG. Early second-trimester maternal hyperandrogenemia and subsequent preeclampsia: a prospective study. Acta Obstet Gynecol Scand. 2005;84(2):117–121.
66.
SowersMRWilsonALKardiaSRChuJFerrellR. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med. 2006;119(9 suppl 1):S23–S30.
67.
SomnerJMcLellanSCheungJPolymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2004;89(1):344–351.
68.
KidokoroKInoKHiroseKAssociation between CYP19A1 polymorphisms and sex hormones in postmenopausal Japanese women. J Hum Genet. 2009;54(2):78–85.
69.
HertigALierePChabbert-BuffetN. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol. 2010;203(5):477 e471–477 e479.
70.
Czajka-OraniecISimpsonER. Aromatase research and its clinical significance. Endokrynol Pol. 2010;61(1):126–134.
71.
SimpsonERClyneCRubinGAromatase--a brief overview. Annu Rev Physiol. 2002;64:93–127.
HongYLiHYuanYCChenS. Molecular characterization of aromatase. Ann N Y Acad Sci. 2009;1155:112–120.
74.
ZhouHFuGYuHPengC. Transforming growth factor-beta inhibits aromatase gene transcription in human trophoblast cells via the Smad2 signaling pathway. Reprod Biol Endocrinol. 2009;7:146.
75.
WilliamsMAWoelkGBKingIBJenkinsLMahomedK. Plasma carotenoids, retinol, tocopherols, and lipoproteins in preeclamptic and normotensive pregnant Zimbabwean women. Am J Hypertens. 2003;16(8):665–672.
76.
ZhuSJLiYLiHRetinoic acids promote the action of aromatase and 17beta-hydroxysteroid dehydrogenase type 1 on the biosynthesis of 17beta-estradiol in placental cells. J Endocrinol. 2002;172(1):31–43.
77.
MilczarekRSokolowskaEHallmannAKlimekJ. The NADPH- and iron-dependent lipid peroxidation in human placental microsomes. Mol Cell Biochem. 2007;295(1-2):105–111.
78.
MollaceVMuscoliCMasiniECuzzocreaSSalveminiD. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57(2):217–252.
79.
JiangBKamatAMendelsonCR. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (mammalian achaete-scute homologous protein-2). Mol Endocrinol. 2000;14(10):1661–1673.
80.
CaniggiaIWinterJL. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies—a review. Placenta. 2002;23(suppl A):S47–S57.
81.
TaoMHCaiQZhangZFPolymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2007;16(5):943–949.
82.
MaCXAdjeiAASalavaggioneOEHuman aromatase: gene resequencing and functional genomics. Cancer Res. 2005;65(23):11071–11082.
83.
NagarSWaltherSBlanchardRL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006;69(6):2084–2092.
84.
NowellSFalanyCN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene. 2006;25(11):1673–1678.
85.
AdjeiAAThomaeBAProndzinskiJLEckloffBWWiebenEDWeinshilboumRM. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol. 2003;139(8):1373–1382.
86.
AksoyIAWoodTCWeinshilboumR. Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochem Biophys Res Commun. 1994;200(3):1621–1629.
87.
SongWCMooreRMcLachlanJANegishiM. Molecular characterization of a testis-specific estrogen sulfotransferase and aberrant liver expression in obese and diabetogenic C57BL/KsJ-db/db mice. Endocrinology. 1995;136(6):2477–2484.
88.
FalanyJLAzzizRFalanyCN. Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chem Biol Interact. 1998;109(1-3):329–339.
